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Background: We have shown that HIV-1 Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters is key to
IFN-stimulated genes (ISG) activation in immature dendritic cells and macrophages.
Results: We evaluated how Tat alleles and mutants differ in cellular gene modulation of immature dendritic cells
and monocyte-derived macrophages and what similarities this modulation has with that induced by interferons.
The tested alleles and mutants modulated to different degrees ISG, without concomitant induction of interferons.
The first exon TatSF21-72 and the minimal transactivator TatSF21-58, all modulated genes to a significantly greater
extent than full-length wild type, two-exon Tat, indicating that Tat second exon is critical in reducing the innate
response triggered by HIV-1 in these cells. Mutants with reduced LTR transactivation had a substantially reduced
effect on host gene expression modulation than wild type TatSF2. However, the more potent LTR transactivator
TatSF2A58T modulated ISG expression to a lower degree compared to TatSF2. A cellular gene modulation similar
to that induced by Tat and Tat mutants in immature dendritic cells could be observed in monocyte-derived
macrophages, with the most significant pathways affected by Tat being the same in both cell types. Tat expression
in cells deleted of the type I IFN locus or receptor resulted in a gene modulation pattern similar to that induced in
primary immature dendritic cells and monocyte-derived macrophages, excluding the involvement of type I IFNs in
Tat-mediated gene modulation. ISG activation depends on Tat interaction with MAP2K3, MAP2K6, and IRF7
promoters and a single exon Tat protein more strongly modulated the luciferase activity mediated by MAP2K3,
MAP2K6, and IRF7 promoter sequences located 5′ of the RNA start site than the wild type two-exon Tat, while a
cysteine and lysine Tat mutants, reduced in LTR transactivation, had negligible effects on these promoters. Chemical
inhibition of CDK9 or Sp1 decreased Tat activation of MAP2K3-, MAP2K6-, and IRF7-mediated luciferase transcription.
Conclusions: Taken together, these data indicate that the second exon of Tat is critical to the containment of
the innate response stimulated by Tat in antigen presenting cells and support a role for Tat in stimulating cellular
transcription via its interaction with transcription factors present at promoters.
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Tat is among the first genes expressed during HIV-1
infection and functions as a transcription elongation
factor for viral gene expression [1-4]. It is also expressed
before integration of the infecting viral genome [5].
Most of the evidence on Tat function has been obtained
in experiments carried out with an 86 amino acid Tat
protein derived from the laboratory-adapted HIV-1 strains
HXB2 or NL4-3, although in most primary strains Tat is a
101 amino acid protein. The first exon of 72 amino acids
is sufficient for transactivation of the HIV LTR and con-
tains a basic domain and a cysteine-rich domain, whose
cysteines are critical to protein function [6-8]. Deletion of
the second exon, which can vary in size, does not substan-
tially affect HIV-1 LTR transactivation in transfection
assays but leads to reduce viral replication and activation
of NF-kB [9]. Two domains in this exon, (RGD and
ESKKKVE), are highly conserved between human and
other primate lentiviruses, but their significance is not
fully understood. Furthermore, findings from HIV-2
and SIV Tat suggest that this exon also contributes to
optimal transactivation and to chronic SIV replication
in vivo [10-12].
Tat increases HIV-1 gene expression by functioning as
an elongation factor and interacting with TAR, a RNA
sequence present at the beginning of the HIV viral
transcripts, and with the host cell factors CDK9 and
cyclin T1, which promotes auto-phosphorylation of the
C-terminus of CDK9 [3,4,13-18]. CDK9 is the catalytic
subunit of P-TEFb, which phosphorylates the C-terminal
domain of the large subunit of RNA polymerase II,
which in turn affects transcript elongation [3]. Tat is also
thought to interact with additional transcriptional regu-
lators, including the protein kinase PKR, Sp1 and the
transcriptional coactivators p300 and the CREB-binding
protein (CBP) [4,19-21]. The interaction of Tat with
these key host cell transcriptional regulators might be
expected to also affect host cell gene expression. Indeed,
there is considerable evidence that Tat can affect the
physiology of T lymphocytes, neurons and antigen pre-
senting cells [22-26]. For example, exposure of peripheral
blood mononuclear cells to exogenous Tat, which can
bind and enter uninfected cells, affects proliferative
responses after exposure to recall antigens [25,26]. The
evidence that Tat can influence host cell behavior makes it
important to determine precisely how Tat affects the gene
expression program of its various host cells.
We explored the effects of HIV-1 and its Tat transacti-
vator on myeloid immature dendritic cells (iDC) and
found that HIV-1 infection or Tat production can induce
expression of ISG [23]. Several of the genes induced by
HIV-1 and its Tat transactivator encode chemokines that
recruit activated T-cells and macrophages, the ultimate
target cells for the virus. HIV-1 Tat can reprogram hostdendritic cell gene expression to facilitate expansion of
the infection and by itself can recapitulate the virus-
induced expression of ISG [23]. Activation of ISG is
mediated by Tat interaction with the promoters of two
kinases, MAP2K3 and MAP2K6, and of IRF7 [27]. Se-
quences upstream of the RNA start site are sufficient for
the Tat-mediated increased transcription of these genes.
The consequence of these interactions is the activation
of p38MAPK- and IRF7-regulated pathways [27]. A Tat-
mediated species-specific increase in ISG was observed
in human and Rhesus macaque iDC and monocyte-
derived macrophages (MDM) but not in the same cells
from Sooty Mangabey (SM) and African Green Monkeys
(AGM), in which SIV establishes a persistent non patho-
genic infection [28]. Our results link the differential in-
duction of ISG to species-specific differences in disease
susceptibility. We also found that in HIV-infected primary
CD4+ T-cells apoptosis is triggered by the Tat-dependent
activation of PTEN-FOXO3a-Egr1 and p53 pathways,
which converge on the FOXO3a transcriptional activator
and that this activation provides a mechanism for HIV-1-
associated CD4+ T cell death [23,29]. Therefore Tat can
affect different cellular pathways in different cell types,
suggesting that interaction with cellular proteins differ-
entially available or cell-dependent chromatin accessibil-
ity may be critical to the observed gene modulation.
To investigate which domains of Tat are critical to the
host-pathogen interactions that are Tat-dependent dur-
ing HIV infection, we evaluated a variety of Tat-mutants
and found that in antigen presenting cells (APCs) as
iDC and MDM, the second exon of Tat reduces innate
immune responses that are maximal when a single exon
Tat is expressed. This suppression could be critical to
modulate virus production in these cells. Furthermore
the analysis of Tat mutants supports a mechanism of
Tat-transactivation of cellular genes similar, but not
identical, to that described to increase HIV LTR-driven
gene expression.Results
Our previous finding indicated that HIV Tat can affect
the gene expression of iDC and induce expression of
some of the ISG [23] via interaction with MAP2K3 and
MAP2K6, and with IRF7 [27]. Promoter sequences located
5′ of the RNA start site are sufficient to observe an in-
crease transcription of a reporter gene but Tat-mediated
modulation is unlikely due to direct DNA binding and
more likely dependent on the interaction with transcrip-
tion factors [27]. In order to characterize which domains
of the Tat protein are critical to cellular gene modulation
we used a combination of genetic and biochemical
approaches aimed at mapping the role of different Tat
domain in cellular gene modulation.
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gene expression more significantly than wild type Tat
Tat alleles and mutants with different phenotypes have
been described extensively [27,30-36]. We reasoned that
testing these known alleles and mutants in modulation
of cellular transcription would permit a comparison with
their effect on viral transcription from the HIV LTR.
Three Tat alleles and six mutants were cloned into an
adenovirus vector and the derived viruses were tested
for Tat protein expression and transactivation activity of
the Tat protein they express (Figure 1). The Tat gene
present in these adenoviruses is under the control of a
tet promoter and the expression of Tat mRNA requires
the expression of the tet transactivator (tTA) in cells.
One of the Tat proteins used in these experiments was
from HIV-1HXB2, which is a clone of HIV-1LAI that was
adapted to cell-culture [37,38]. Because of a premature
termination codon in the second exon, TatHXB2 has 86
amino acids instead of the 101 typically found in Tat of
HIV-1 of patients, for instance TatSF2 (Figure 1A). The
TatHXB2 was less efficient in LTR transactivation than
TatSF2 (Figure 1C). Comparison of these Tat alleles
should reveal how the modulation induced by the Tat
protein from a cell culture-adapted virus differs from
that of a Tat protein more common in patients. HIV-
1SF13 replicates faster than HIV-1SF2 and TatSF13 is a
more potent transactivator than TatSF2 [30]. The amino
acid causing the difference between the two was mapped
to position 58 (Figure 1A) [30]. The A58T mutation in
TatSF2A58T recapitulates the transactivation properties
of TatSF13 (Figure 1C). If Tat transactivates host genesB 
A 
-ac
 Tat (
Figure 1 Recombinant adenoviruses were generated expressing three
TatSF2 mutants. Amino acids that differ from the wild-type TatSF2 are in bol
mutant in iDC. (C) The three Tat alleles and six Tat mutants were expressed
the HIV-1 LTR promoter. Transactivation activity was measured by a β-galacvia the same mechanism used for the transactivation of
HIV-1 genes under the LTR promoter TatSF2A58T should
differ from TatSF2 in its effect on host gene expression.
We generated two Tat mutants lacking the second
exon: TatSF21-72 and TatSF21-58 (Figure 1A). TatSF21-72
has all the amino acids encoded by the first exon.
TatSF21-58 is the minimal transactivator [31,32]. Tat mu-
tants that have less than the 58 amino-terminal residues
are no longer able to transactivate genes under the HIV-
1 LTR promoter. Comparing the effect of these mutants
to wild-type TatSF2 should reveal what role the second
exon plays in modulation of host gene expression.
TatSF21-72 caused lower LTR transactivation than wild
type TatSF2 and transactivation was also present at 19%
of the amount observed with TatSF2 with the minimal
transactivator TatSF21-58 (Figure 1C). TatSF2C25,30,34S
(Figure 1A) did not transactivate the lacZ gene control-
led by the HIV-1 LTR promoter (Figure 1C). Lysine resi-
dues at positions 28 and 50 are acetylated by the
histone acetyl transferases (HAT) p300 and p300/CBP-
associating factor (PCAF) and the latter also interacts
with hGCN5 [33-35]. The Ad-TatSF2K28,50A mutant
(Figure 1A) was used to investigate whether histone
acetylation plays in regulation of the host transcrip-
tome. These mutations lowered LTR transactivation
(Figure 1C). Comparing these mutants to the wild type
should tell us whether host gene transcription is transac-
tivated by a similar mechanism as HIV-1 genes. HIV
and SIV Tat proteins have a highly conserved amino
acid motif, ESKKKVE in their C-terminus. In the
mutant TatSF2E86-E92A this region was substituted withC
tin 
-Flag) 
alleles and six mutants of Tat. (A) Sequences of the Tat alleles and
d and underlined. (B) Western Blot analysis of Tat alleles and
in HeLa cells that have the β-galactosidase gene under the control of
tosidase assay and compared to the activity of the wild-type TatSF2.
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this conserved motif is important in modulation of the
host transcriptome. These mutations lowered the LTR
transactivation activity to a level similar to the minimal
transactivator (Figure 1C). We also utilized the mutant
TatSF2G48-R57A (Ad-TatSF2G48-R57A), in which the nu-
clear localization signal residues 48 to 57 were substituted
by alanines [27,36]. This mutant does not enter the nu-
cleus and therefore cannot affect cellular transcription,
providing a significant negative control in gene expression
experiments.
We evaluated the steady state accumulation of Tat
alleles and mutants in iDC by Western Blot and studied
the subcellular localization of the FLAG-tagged versions
of these mutants by immunofluorescence microscopy.
All Tat proteins accumulated approximately at similar
levels (Figure 1B) and localized in the nucleus with the
exception of mutant TatSF2G48-R57A (not shown).
In our previous experiments Ad-TatHXB2 caused the
induction of ISG in iDC [23,28]. To investigate how differ-
ent Tat alleles and Tat mutants differ in their effect on host
gene expression, human monocytes were differentiated
into iDC, and then infected with the Tat-expressing adeno-
viruses and Ad-tTA alone as a control. Cellular gene ex-
pression was investigated in RNA isolated 5, 10, and 20 h
post-infection with the Affymetrix Human Genome U133
Plus 2.0 Array. The results for Tat alleles and mutants were
compared to HIV-1 infection of iDC collected 10 and
14 days post infection and previously analyzed with the
Affymetrix Human Genome U133 Array (HG 133). In pre-
vious experiments Ad-Tat caused the up-regulation of ISG
[23]. Therefore, to compare the mimicry of interferons
caused by Tat to the effects caused by Type I and II inter-
ferons, we also treated iDC with interferon α, β, and γ.
We focused on transcripts whose expression levels
changed at least two-fold at two consecutive time points
or 3-fold or more at one time point in any of the Tat
alleles or mutants compared to those modulated by the
control Ad-tTA. Expression of TatSF2 caused the up-
regulation of sixty-seven genes and the down-regulation
of nine genes according to these criteria (Figure 2).
When an Ingenuity Pathway Association analysis (IPA)
of this group of genes was carried out we found sig-
nificant association with the canonical pathway and the
biological functions listed in Table 1. The various Tat
alleles and mutants modulated similar sets of host genes
but the extent of gene modulation differed (Table 2).
TatSF21-72 and TatSF21-58 caused more significant gene
modulation than the wild type Tat alleles and mutants
that retain the second exon. This was true when the data
were analyzed in a number of ways: a larger number of
genes were affected (Table 2), the changes in levels of
transcription were of larger magnitude (Figure 2A, B),
and the significance of modulation of different pathwayswas higher (Table 2, data reported for gene function
annotation associated with mechanism of infection). The
TatHXB2 allele, which has a shortened second exon
encoding 14 amino acids instead of the 29 in TatSF2, also
caused a more extensive gene modulation than the wild-
type TatSF2. This indicates that the amino acids encoded
by the second exon of Tat diminish the impact Tat has
on host gene expression. TatSF2A58T, which recapitu-
lates the phenotype of TatSF13, modulated similar sets of
genes but to a lower degree than TatSF2. TatSF2A58T is a
more potent transactivator of genes expressed under the
control of the HIV-1 LTR promoter than TatSF2 [30].
The mutant TatSF2K28,50A and TatSF2C25,30,34S, which
are both inactive in LTR transactivation, caused signifi-
cantly less gene modulation of the host transcriptome
than the wild-type TatSF2 (Figure 2 and Table 2). The
mutations in the conserved region in the second exon
encoding, introduced in the Ad-TatSF2E86-E92A mutant,
also reduce substantially the effect of Tat on host gene
expression (Figure 2 and Table 2). As this domain is
deleted in TatHXB2 and deletion of entire second exon
actually increases Tat-mediated gene modulation, indi-
cating that this entire exon is not necessary for this
function, it is possible that these residues play a role in
the correct folding of Tat and the introduced mutations
disrupt its structure too drastically to be compatible with
function. Therefore this mutant does not provide any
information in the role played by this domain of Tat in
gene modulation.
Many but not all of the genes up-regulated by the HIV
TatSF2 could also be found modulated by interferons.
However the patterns observed when cells were exposed
to Type I and Type II IFN were different, and consisted
of a larger number of genes modulated to a higher degree.
The comparative analysis revealed that TatSF21-72 modu-
lation pattern correlated more closely is with IFN-β (R2 =
0.6630) than IFN-α (R2 = 0.4580) or IFN-γ (R2 = 0.2948)
and that type I IFNs are more similar to each another
in their impact on gene modulation (IFN-α vs. IFN-β
R2 = 0.8833; IFN-α vs. IFN-γ R2 = 0.2290; IFN-β vs.
IFN-γ R2 = 0.3158) than to Tat. However, Tat and Type I
IFN patterns are dissimilar enough to make it unlikely that
the effects observed in presence of Tat are due to stimula-
tion of IFN production. Indeed, no expression of Inter-
feron α, β, or γ genes could be detected by RT-qPCR and
the corresponding proteins were not detected in the
supernatant of TatSF2 expressing iDC (not shown).
The effect that Tat alleles and mutants had on host
gene expression was analyzed also by RT-qPCR in iDC.
RNA was isolated at multiple time points post-infection
and the following RNAs were quantified: glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), as a control gene
used for normalization, Tat, to correct for possible dif-
ferences in infectivity, and a subset of ISG that includes
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Figure 2 ISG modulation by Tat alleles and mutants in iDC. A. RNA expression analysis in iDCs expressing Tat alleles and mutants. Gene
expression fold induction is shown for RNA isolated 10 h after adenovirus infection or interferon treatment, and 10 and 14 days after HIV-1 infec-
tion. Data for HIV-1 infection, previously published [23], are included here for direct comparison. GAPDH levels were used to normalize the results
of the individual samples. B. Microarray mRNA levels of selected ISG in iDC expressing Tat alleles and mutants or exposed to IFNs (10 h time
point). RNA fold change is reported as the ratio of the signal in the experimental sample compared to the control. C. Gene expression analysis of
selected ISG RNA levels by RT-PCR (upper panel) and protein levels by ELISA (lower panel, 20 h post-infection) in cell lysates and their respective
supernatants of iDC from five donors. RNA fold change compared to that of control cells infected with Ad-tTA, was evaluated using the threshold
cycle (Ct) number normalized for β-actin Ct.
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modulated in the microarray expression analysis. The
mutants lacking the second exon, TatSF21-72 and
TatSF21-58, caused a more pronounced up-regulation of
the four-cytokine mRNAs 20 h post-infection than
TatSF2 (Figure 2C, top). We next evaluated changes at
the protein level of some ISG by measuring by ELISA
the amount of IP-10, MCP-2, and HuMig in the growth
medium. The ELISA results were similar to the RT-
qPCR, confirming that the highest expression levels were
found with the mutants lacking the second exon,
TatSF21-72 and TatSF21-58 (Figure 2C, bottom). We con-
cluded that a single exon- or a shorter Tat, down to a
size still competent of LTR transactivation (58 aa-Tat),has the greatest effect on cellular gene modulation while
the presence of the second exon of Tat substantially re-
duces cellular gene modulation, in particular the induc-
tion of cytokines that are part of the innate response
triggered in iDC by viruses.
Comparative analysis of Tat-mediated gene expression
modulation in iDC and MDM
Previous observations indicated that HIV infection of
MDM also induces a significant number of ISG and that
this effect can be attributed to Tat [39-42]. To extend
our observation to antigen presenting cells that derive
from the same lineage as iDC we evaluated the modula-
tion of gene expression using HIV-1 infection and
Table 1 Ingenuity systems pathway analysis of genes found modulated by HIV and Tat in primary iDC and MDM
Ingenuity canonical pathways p-value
iDC MDM Common to both
Interferon signaling 7.59E-09 9.94E-10 2.54E-11
Pathogenesis of multiple sclerosis 4.44E-08 1.45E-07 1.05E-09
Role of pattern recognition receptors in recognition of bacteria and viruses 1.24E-06 3.95E-07 2.51E-07
Activation of IRF by cytosolic pattern recognition receptors 9.36E-06 3.87E-05 4.93E-06
Ingenuity biological functions
Antimicrobial response 8.44E-12 2.68E-10 2.82E-11
Cell-mediated immune response 2.35E-10 7.57E-08 1.23E-10
Immune cell trafficking 2.35E-10 7.57E-08 1.23E-10
Infection mechanism 4.35E-08 1.45E-07 1.05E-09
Antigen presentation 4.10E-09 7.72E-07 2.09E-08
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phages derived from the monocytic cell line THP-1
(THP-Mac) and in primary MDM, in which we con-
firmed those observations (Figure 3A). We also focused
on the genes similarly regulated by HIV and TatHXB2 that
were differentially regulated when compared to the
control and were at least two-fold upregulated or down-
regulated. 136 genes fit this definition (Figure 3A, B).
When a subset of genes was investigated in three inde-
pendent donors, we confirmed that although there is
donor variability, the induction of a subset of ISG is
detected across different donors (not shown). The IPA
analysis for these genes is reported in Table 1. To extend
these observations to a Tat protein from a different
strain, HIV-1Bal and evaluate the effect of one vs. two
exon Tat in MDM, we also investigated how TatSf2 and
TatBal and their corresponding single-exon, 72 amino
acid Tat proteins modulate expression of a subset of ISGTable 2 Ingenuity systems pathway analysis of genes
found up-regulated by Tat and mutants iDC
# Upregulated # Downregulated Infection
mechanism
(p-value)
Ad-TatSF2 67 9 3.30E-06
Ad-TatSF2A58T (SF13) 49 12 5.63E-05
Ad-TatHXB2 113 15 2.20E-12
Ad-TatSF21-72 205 31 1.57E-14
Ad-TatSF21-58 291 121 6.51E-16
Ad-TatSF2C20,25,34S 41 7 1.28E-02
Ad-TatSF2K28,50A 26 7 1.37E+00
Ad-TatSF2E86-92A 47 19 1.18E+01
IFN-α 100 U/ml 103 9
IFN-β 100 U/ml 248 49
IFN-γ 100 U/m 347 126
Type I IFNs 4.69E-10by quantitative RT-PCR. We found that TatBal was simi-
lar to TatSF2 in its cellular gene modulation and that, as
observed in iDC, the single-exon Tat protein modulated
most of these genes to a significantly higher degree.
When the cumulative levels of gene expression of all the
ISG genes stimulated by the one-exon Tat were com-
pared to that stimulated by the wild type Tat the differ-
ence of this modulation was statistically significant for
both Tat alleles (p < 0.0001 for TatSF2 and TatSF21-72 and
p < 0.0004 for TatBal and TatBal1-72) (Figure 3C).
Although not identical, there were significant similar-
ities between the sets of genes modulated by HIV and
Tat in iDC and in MDM (Figure 3D). The subset of
genes similarly regulated in iDC and MDM are listed in
Table 3. Their association with specific cellular path-
ways, including the statistical significance of the associ-
ation, is also reported (Table 1, last column). The most
significantly affected pathways were interferon signaling,
activation of IRF by cytosolic pattern recognition recep-
tors (PRR), and role of PRR in recognition of bacteria
and viruses. This comparative analysis indicates that Tat
can modulate the innate response that pathogens trigger
in both types of APC and that utilizes the second exon
to contain the extent of such response.Tat-mediated modulation of ISG does not require Type I
IFN production
In iDC half of the 291 genes that were up-regulated by
TatSF21-58 were also up-regulated by interferon (IFN)-α
or IFN-β. Furthermore, half of the 121 down-regulated
genes by IFN-α or IFN-β were also similarly affected by
Tat (Figure 2A). It is reasonable to assume that the in-
duction of ISG upon HIV infection or Tat expression
could results from the induction of IFN. As mentioned
above, interferons could not be detected in the superna-
tants of iDC or MDM cultures by ELISA or at the RNA
level by RT-qPCR. However it is possible that amounts
A B
C
D
Figure 3 Comparative analysis of Tat-mediated gene modulation in iDC and MDM. A. Microarray RNA levels in MDM infected with
Ad-TatSF2 or Ad-TatHXB2 (left panel) and in MDM infected with Ad-TatHXB2 for 30 h or with HIVBal for 7 and 10 days (right panel). B. Venn diagrams
representing total number of genes modulated by Tat or HIV-1 in MDM and the overlapping subset similarly modulated in the two conditions.
C. Modulation of a subset of ISG in MDM evaluated by quantitative RT-PCR. TatSF2 and TatSF272 were expressed using an adenoviral vector and
RNA was purified 16 and 30 h after infection. TatBal, and TatBal1-72 were expressed using a lentiviral vector and RNA was purified 30 and 48 h after
infection from cells sorted 24 h after infection using a GFP maker present in the lentivector. Results are reported as the average (n-fold) induction
of three independent experiments relative to that of the control sample infected with the background vector. Values are normalized using 18S
RNA and Tat levels. Significant differences between the cumulative levels of all the evaluated ISG expressed in TatSF2 and in TatSF21-72 were
detected at 16 and 30 h (p < 0.0001 for both time points, T-test) and also between TatBal, and TatBal1-72 at 30 (p = 0.0004) and 48 h (p < 0.0001).
Significant differences could also be detected when individual gene expression was compared. P values for gene fold inductions in TatSF21-72
samples compared to TatSF2 were: IRF7-16 h: p = 0.03, IRF7-30 h: p = 0.006; STAT1-16 h: p = 0.04, STAT1-30 h: p = 0.03; IP10-30 h: p = 0.04;
MIG-16 h: p = 0.0001, MIG-30 h: p = 0.03; TRAIL-16 h: p = 0.04; ISG20-16 h: p = 0.02, ISG20-30 h: p = 0.002; CCL20-16 h: p = 0.003, CCL20-30 h:
p = 0.03; IFI35-16 h and 30 h: p = 0.03; RSAD2-30 h: p = 0.01; OASL-16 h: p = 0.01, OASL-30 h: p = 0.008. P values for gene fold inductions in the
TatBal samples compared to the TatBal1-72 were: MCP3-30 h: p = 0.008; TRAIL-30 h: p = 0.002; ISG20-30 h: p = 0.01; IFI35-30 h: p = 0.05, IRF7-48 h:
p = 0.02; STAT1-48 h: p = 0.02; MIG-48 h: p = 0.02. D. Number of genes modulated by Tat and HIV-1 in MDM and in iDC and subset similarly
modulated in the two cell types.
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Table 3 Lists of genes similarly modulated by HIV and Tat in iDC and MDM
Gene symbol Entrez gene name Gene bank
AIF1 Allograft inflammatory factor 1 NM_004847
ATF3 Activating transcription factor 3 AB066566
BST2 Bone marrow stromal cell antigen 2 NM_004335
CCL3 Chemokine (C-C motif) ligand 3 NM_002983
CCL5 Chemokine (C-C motif) ligand 5 AF043341
CCL7 Chemokine (C-C motif) ligand 7 NM_006273
CCL8 Chemokine (C-C motif) ligand 8 AI984980
CDC20 Cell division cycle 20 homolog (S. cerevisiae) NM_004295
CXCL10 Chemokine (C-X-C motif) ligand 10 NM_001565
CXCL9 Chemokine (C-X-C motif) ligand 9 NM_002416
HSPA6 Heat shock 70kDa protein 6 (HSP70B') NM_002155
IDO1 Indoleamine 2,3-dioxygenase 1 M34455
IFI27 Interferon, alpha-inducible protein 27 NM_005532
IFI35 Interferon-induced protein 35 BC001356
IFI44 Interferon-induced protein 44 NM_006417
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 AA131041
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 AI075407
IRF7 Interferon regulatory factor 7 NM_004030
ISG15 ISG15 ubiquitin-like modifier NM_005101
KPNB1 Karyopherin (importin) beta 1 AC004941
LY6E Lymphocyte antigen 6 complex, locus E NM_002346
MX1 Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) NM_002462
MX2 Myxovirus (influenza virus) resistance 2 (mouse) NM_002463
OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa NM_001255
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa NM_002535
OASL 2'-5'-oligoadenylate synthetase-like NM_003733
SLC11A2 Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2AF046997
SLC1A2 Solute carrier family 1 (glial high affinity glutamate transporter), member 2 NM_004171
STAT1 Signal transducer and activator of transcription 1, 91kDa BC002704
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 AI738896
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 NM_007115
TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 AW474434
TRIM22 Tripartite motif containing 22 AA083478
USP18 Ubiquitin specific peptidase 18 NM_017414
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To test whether gene modulation could occur in the ab-
sence of type I interferons, we evaluated the effect of Tat
expression in two cell lines that can be differentiated
into iDC, K562 and U5A. The first is a human erythro-
myeloblastoid leukemia cell line derived from a chronic
myeloid leukemia patient in blast crisis in which the
entire Type I IFN locus is deleted [43]. In U5A cells the
type I IFN receptor chain 2 is deleted [44,45]. In iDC
derived from these lines the induction of a subset of ISG
could be detected both at RNA and protein levels afterTat expression (Figure 4). The expression of TatSF2 in K562
cells, monitored by RT-qPCR, resulted in increased mRNA
levels of all the genes we tested. (Figure 4A, B). The tran-
scription factor IRF7 was up-regulated in these cells as it
was in primary iDC infected with TatSF2. We also observed
up-regulation of IP-10, measured by ELISA, and TRAIL,
measured by intracellular staining (ICS) and reported as me-
dian fluorescence intensity (MFI) (Figure 4C and D). As in
primary cells, the expression was significantly higher when
the TatSF21-58 was expressed. When modulation of cellular
genes by Tat expression was evaluated in U5A cells, which
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Figure 4 Induction of ISG by HIV TatSF2 in K562 and U5A cells (4E-4H) cells. Detection of Tat RNA expression by RT-qPCR in K562 and
U5A cells 16 and 30 h (A) and 30 h (E) after adenoviral infection. B. Detection of ISG RNA expression by RT-qPCR after adenoviral infection in
K562-DC at 16 and 30 h. Statistical significance was detected by T Test when comparing TatSF2 and TatSF21-58 values at 16 h for IRF-7 (p = 0.02),
and for the ISG RNA values grouped together (p = 0.0007); at 30 h for IP-10 (p = 0.04), MCP2 (p = 0.05), MIG (p = 0.049), TRAIL (p = 0.01), and for
the ISG RNA values grouped together (p = 2.19E-06). C. IP10 ELISA of TatSF2 and TatSF21-58 expressing K562 supernatants; p = 0.0002 by ANOVA
and Bonferroni’s multiple comparison test was significant for all pairs except UI and tTA; significant differences were also found by T-Test
between, tTA and TatSF2 (p = 0.05), tTA and TatSF21-58 (p = 0.0001) and TatSF2 and TatSF21-58 (p = 0.047). D. Protein analysis of TRAIL levels by ICS
in K562: tTA and TatSF2 (p = 0.043, T-Test) and TatSF2 and TatSF21-58 (p = 0.041). F. Detection of ISG RNA expression by RT-qPCR after adenoviral
infection in U5A cells at 30 h. Statistical significance was detected when comparing TatSF2 and TatSF21-58 values for IRF-7 (p = 0.03,T-Test), IP-10
(p = 0.01), TRAIL (p = 0.02), and for the cumulative values of all the ISG (p = 0.0046). G. IP10 ELISA of TatSF2 and TatSF21-58 of infected U5A
supernatants; p = 0.0008 by 1-way ANOVA, Bonferroni’s multiple comparison test was significant for all pairs except UI and tTA; significant differences
were also found by T-Test between tTA and TatSF21-58, (p = 0.003), tTA and TatSF2 (p = 0.008) and TatSF2 and TatSF21-58 (p = 0.01). H. Protein
analysis of TRAIL levels by ICS in K562: tTA and TatSF2 (p = 0.03, T-Test) and TatSF2 and TatSF21-58 (p = 0.04, T-test). RNA fold induction represents the
ratios between the RT-PCR result obtained for cells expressing Tat or Tat1-58 and that obtained for Ad-tTA infected cells. Ct values in all samples were
normalized using β-actin expression levels. Tat amount in the 30 h wild-type TatSF2 infected sample was assigned an arbitrary value of 1.
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to those observed in K562 and confirmed the IFN-inde-
pendent activation of ISG (Figure 4E-H). These results in-
dicate that HIV Tat expression results in modulation of
ISG and that this induction is not the result of production
of IFN-α or IFN-β. Therefore we can conclude that Tat
can modulate an innate immune response similar to that
stimulated by Type I IFNs in the absence of any IFN.
Tat modulation of ISG depends on interactions with cellular
transcription factors
We reported that Tat activation of ISG is mediated by
Tat association with the promoters of MAP2K6 and
MAP2K3, which activate p38MAPK, and of IRF7 [27].
This association leads to an increased accumulation ofthe corresponding RNAs and, in turn, to activation of
the ISG [27]. Increased luciferase activity was observed
when the luciferase gene was controlled by the MAP2K3,
MAP2K6 or IRF7 promoter sequences and Tat was
expressed in the APC [27]. In these constructs approxi-
mately 1000 bases of promoters sequences upstream the
RNA start site were cloned at the 5′ of the luciferase gene
[27]. Here we investigated to what degree the single-exon
TatSF21-72 affected luciferase activity when its transcrip-
tion is dependent from these promoters. Activation of the
MAP2K3-Luc, MAP2K6-Luc, and IRF7-Luc promoter
constructs was tested in THP-Mac cells using different
Tat proteins. We found that luciferase activity was signifi-
cantly higher in the presence of TatSF21-72 than of wild
type TatSF2 and that mutants in which the interaction with
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TatSF2C25,30,34S or TatSF2K28,50A, could not stimulate
luciferase activity at levels higher than those observed with-
out any Tat protein (Figure 5A). These results are in agree-
ment with the more robust activation of ISGs observed by
this Tat mutant in iDC and MDM (Figures 2, 3C). We also
found that there is variability in the level of stimulation of
each of these promoters in cells from different donors (not
shown). However, as all three gene products, MAP2K3,
MAP2K6, and IRF7, can contribute to the activation of
ISGs, these individual differences do not significantly affect
the end result, when the induction of ISG is evaluated in
different donor cells.
Tat interacts with cellular transcriptional regulators
and it is possible that the increased transcriptional activity
mediated by of MAP2K3, MAP2K6, and IRF7 promoters in
the presence of Tat is a result of these interactions. To
evaluate whether Tat-mediated gene expression modulation
is affected when cellular transcription factors are inhibited,
we used specific inhibitors to interfere with the function of
P-TEFb, a factor required for cellular gene transcription,MAP2K3 MAP2K6C 
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Figure 5 Tat modulation of ISG requires P-TEFb and Sp1. A. Luciferase
exon TatSF21-72, TatSF2C25,30,34S or TatSF2K28,50A and transfected with IRF
in the transfected vector is indicated above the bars). Significantly different
TatSF21-72 for all three promoters (MAP2K3: p = 0.04; MAP2K6: p = 0.03; IRF7
expressing the wild-type TatSF2, the single exon TatSF21-72 and transfected
indicates treatment with Flavopiridol (70 nM). C. Luciferase activity in lysate
transfected with MAP2K3, MAP2K6-, or IRF7-luciferase reporter vectors in th
treatment with WP631 (0.3 ug/ml). D, E. Western Blot of Tat expressing cell
(D) or with WP631 (E). Dotted lines indicate pairs of values with statisticallyor Sp1, as all three promoters under investigation contain
Sp1 binding sites. When THP-Mac transfected with the lu-
ciferase vectors were also exposed to Flavopiridol, inhibitor
of CDK9 and therefore of P-TEFb [46], or WP631, inhibitor
of Sp1 [47,48], the luciferase activities associated with both
TatSF21-72 and wild type TatSF2 were significantly reduced
for all promoters (Figure 5B, C). Luciferase activity did
not significantly diminish when compared between
samples from untreated and treated cells that were
not expressing Tat, although luciferase values were
lower in the treated samples. These inhibitors did not
affect Tat or β-actin levels of expression during the 16 h
timeframe of the experiments (Figure 5D, E). We con-
cluded that Tat stimulation of these promoters depends
on Tat interaction with P-TEFb, which is compromised
when the cysteine residues are mutated. Tat interaction
with Sp1 also contributes to Tat-mediated gene modula-
tion of these specific promoters. The one-exon version of
Tat appears more efficient at this process than the wild
type Tat, possibly by facilitating the activation of P-TEFb
and Sp1. 
 IRF7 
E 16 h p.i. 
Tat 
-actin 
16 h p.i. 8 h p.i. 
IRF7 
activity in THP-Mac lysates expressing the wild-type TatSF2, the single
7-, MAP2K6-, or MAP2K3-luciferase reporter vectors (the promoter used
levels of luciferase activity could be detected between TatSF2 and
: p = 0.004, T Test). B. Luciferase activity in lysates from THP-Mac
with MAP2K3-, MAP2K6-, or IRF7-luciferase reporter vectors. “ + Fvp”
s from THP-Mac expressing the wild-type TatSF2 or TatSF21-72 and
e presence or absence of WP631, a Sp1 inhibitor. “ +WP” indicates
s at 8 and 16 h post infection, treated or not treated with Flavopiridol
significant differences.
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of IFN-associated genes more efficiently than wild type HIV
We investigated whether the more significant gene
modulation observed with a single exon Tat compared
to wild type Tat also occurred when a single exon Tat
gene was part of the HIV genome (HIVSF2ΔExon2Tat).
When HIVSF2ΔExon2Tat was used to infect iDC or
MDM and levels of accumulated HIV transcripts inA
B
C
Figure 6 A HIV virus lacking the second Tat exon induces a stronger
7 days after infection with HIVSF2 or HIVSF2ΔExon2Tat. B. ISG RNA levels in i
significance was detected when comparing HIVSF2 and HIVSF2Δexon2Tat RN
(p = 0.019), IP-10 (p = 0.05), TRAIL (p = 0.01), and for the ISG RNA values gro
ISG-related proteins in iDC infected with HIVSF2 or HIVSF2ΔExon2Tat on day
for IRF-7 (p = 0.01), Stat-1 (p = 0.007), MAP2K6 (p = 0.013), IP-10 (p = 0.01), TR
when grouped together (p = 0.0026). D. Tat RNA levels in MDM 7 days afte
infected for 7 days with HIVSF2 or HIVSF2 ΔExon2Tat. Statistical significance
for IRF-7 (p = 0.03), Stat-1 (p = 0.05), MX2 (p = 0.04) and (TRAIL p = 0.05), and fo
levels of ISG-related proteins in MDM infected with HIVSF2 or HIVSF2ΔExon2Ta
found for IRF-7 (p = 0.05), Stat-1 (p = 0.05), TRAIL (p = 0.01), MCP-2 (p = 0.0001
fold induction represents the ratio between the RT-PCR result obtained for ce
RNA amounts are normalized using 18S RNA levels and infection rates are noHIVSF2ΔExon2Tat infected cells were compared to those
obtained with HIVSF2 during a time course, there was
initially a lower accumulation of HIV transcripts in the
culture infected by the mutant. However by day 7-10 the
amount of infected iDC or macrophage cells, estimated by
staining with an anti-gp120 antibody, was similar for
the two viruses and total Tat RNA accumulation varied
little (Figure 6A, D). When ISG gene expression analysisD
E
F
innate response than a wild type virus. A. Tat RNA levels in iDC
DC infected for 7 days with HIVSF2 or HIVSF2 ΔExon2Tat. Statistical
A values for IRF-7 (p = 0.03), Stat-1 (p = 0.006), OAS (p = 0.03,) IL-8
uped together (p = 0.001) (T-test). C. Protein accumulation levels of
7 after infection, reported as MFI. Significant differences were found
AIL (p = 0.01), MCP-3 (p = 0.05), HuMig (p = 0.01), ISG protein values
r infection with HIVSF2 or HIVSF2ΔExon2Tat. E. ISG RNA levels in MDM
was detected when comparing HIVSF2 and HIVSF2ΔExon2Tat RNA values
r the cumulative levels of all the ISG (p = 0.0008). F. Protein accumulation
t on day 7 after infection, reported as MFI. Significant differences were
), HuMig (p = 0.01), ISG protein values grouped together (p = 0.03). RNA
lls expressing Tat or Tat1-58 and that obtained for Ad-tTA infected cells.
rmalized using Tat levels.
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of a number of them was significantly higher in iDC and
MDM infected with HIVSF2ΔExon2Tat compared to the
same cells infected with wild type HIVSF2 (Figure 6B, E).
When the cumulative induction of all the investigated
genes by HIVSF2 was compared to that obtained with
HIVSF2ΔExon2Tat the difference was significant (p =
0.001 in iDC and p = 0.0008 in MDM). A higher level of
induction of the corresponding gene products was also
found when the intracellular protein accumulation was
evaluated by ICS in HIV positive cells. The MFI was sig-
nificantly higher in cells infected by HIVSF2ΔExon2Tat
(Figure 6C, p = 0.0026, 6F, p = 0.03). These data confirm
the observations made with the expression of single exon
Tat in the context of the full length HIVSF2: Tat second
exon reduces the activation of cellular genes stimulated by
Tat first exon.
Discussion and conclusion
HIV infects a variety of cells that are critical components
of the immune system and the outcome of the infection
varies in different cell types. Cells like CD4+ T cells pro-
duce substantial amount of virus and undergo apoptosis,
or die of cytopathic effect, or become latently infected;
macrophages produce substantially less virus than T cells
upon infection but are much more resistant to virus-
mediated cell death; iDC produce even lower amounts
of virus than macrophages and are also resistant to
virus-mediated death. It is therefore logical to envision
that these different cells respond differently to HIV or
SIV infection and manage to do so by different adjust-
ments of their gene expression program to the viral in-
fection. Among the HIV proteins that could directly play
a role in affecting cellular gene expression at the tran-
scription levels there is Tat, a protein that regulates HIV
and SIV gene expression and interacts with important
components of the transcription machinery. We previ-
ously investigated Tat modulation of gene expression in
iDC and T cells [23,29]. Here we compared Tat-mediated
modulation observed in iDC to that of MDM and we ad-
dressed the question of whether specific domains of Tat
are more critical than others in the host-pathogen interac-
tions established by HIV in APCs and whether the induc-
tion of ISG is strictly mediated by Tat or could be
mediated by the induction of IFNs. We found that there
were no major qualitative differences of cellular gene
modulation between the three 101 amino acid Tat pro-
teins tested, both derived from clade B HIVs. Shorter Tat
proteins had a more significant effect on cellular gene
modulation than their full-length counterpart, supporting
the role of Tat second exon in limiting Tat effects on cellu-
lar genes.
The mutants investigated here point at a mechanism
of cellular gene transactivation similar but not identicalto that used to increase efficiency of viral gene expres-
sion. The most important result is the evaluation of
Luciferase activity stimulated by the promoters that are
critical to the induction of ISG by Tat. We have shown
that Tat associates with the promoters of MAP2K3,
MAP2K6 and IRF7 and that this association is critical to
the activation of ISG [27]. As only sequences upstream
the RNA start sites were linked with the Luc gene, it is
unlikely that an interaction with structural elements of
the mRNA of these genes is critical to their transcrip-
tional increase. This is also supported by the fact that
TatA58T that is most efficient in transactivation of the
HIV LTRs is not the most efficient modulator of cellular
genes and it is actually less efficient that TatSF2, TatHXB2
or TatSF21-72, all of which transactivate the HIV LTR at
lower levels than TatSF2A58T (Figure 1). However, the
fact that poor transactivators of the HIV LTR, such as
TatSF2C25,30,34S and TatSF2K28A,K50A, also have a sig-
nificantly lower effect on modulation of cellular genes
and poorly stimulate luciferase activity controlled by
MAP2K3, MAP2K6 and IRF7 promoters suggests that
the interactions with p300 and P-TEFb are important for
cellular gene modulation as they are for HIV efficient tran-
scription. The results observed with the TatSF2K28,50A
mutant support the possibility that Tat acetylation and/or
interaction with histone acetyl transferases are also neces-
sary in order for Tat to modulate host cell mRNA
transcription.
Tat-mediated modulation of cellular promoters appears
to require interaction with P-TEFb, possibly favoring its
switch from inactive to active and bypassing its regulation
by cellular factors. Tat could facilitate promoter-proximal
pause release, as it has been shown for Myc at many
promoters [49,50] and for Tat at the cad promoter, where
it can substitute Myc activation [49]. Each of the three
promoters critical to Tat-mediated ISG activation contains
Sp-1 binding consensus sequences. Therefore it is not
surprising that the Sp1 inhibitor we tested reduced the
luciferase activity they mediate. Tat promotes the phos-
phorylation of Sp1, which increases its binding to target
sequences [19-21]. It is conceivable that Tat interaction
with P-TEFb results in CDK9-mediated phosphorylation
of Sp1, increasing its activity.
The luciferase activity experiments suggest a more im-
portant role of Tat in affecting the rate of RNA initiation
rather than a change in elongation as it occurs at the TAR
element of HIV transcripts. As all these genes are usually
transcribed in the absence of Tat, it is not surprising that
the stringent requirement of Tat to permit elongation of
HIV transcripts does not apply to cellular RNAs. A de-
tailed analysis of the complexes that include Tat at different
promoters and lead to their increased transcription and
what dictates the selectivity of different cellular promoters
in different cell types will be the focus of future studies.
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and the magnitude of modulation was also more sig-
nificant than that observed with a two exon protein.
When coupled with the fact that the second exon is also
necessary for efficient reverse transcription, these results
provide an additional explanation for why a virus with a
single exon Tat is quickly cleared in SIV infected animals
[12]. The stronger innate response induced by a single
exon Tat in infected APCs could facilitate stimulation of
the adaptive response and virus clearance. Furthermore,
among the ISG modulated by Tat are genes that signifi-
cantly reduce retroviral replication such as PKR, OAS,
and MX2, recently shown to have a profound effect on
HIV infectivity [51-53]. The induction of ISG, which
does not happen to the same extent in T cells [29], could
explained the reduced viral replication that occurs in
APC after infection with a wild type virus carrying a full
length Tat, when reverse transcription is equally efficient
in both T cells and antigen presenting cells. It may also
explain why the more significant induction of these
genes by a single-exon Tat and the consequent heighten
ISG induction could further reduced retroviral replica-
tion in iDC and MDM. As the vast majority of infected
T cells dies upon infection, a substantially reduced repli-
cation in APCs may be insufficient to sustain persistent
infection. It is therefore to the virus advantage to modu-
late its replication in these cells in such a way that it is
not too much, and therefore could lead to cell recogni-
tion and elimination by the anti-viral adaptive immunity
or cell death, and not too little, with consequent pro-
gressive decline of viral persistence.
Our studies support the fact that Tat can mimic the role
of IFN and can by itself activate pathways normally
affected by viral pathogens signaling via Toll receptors.
There are a number of reasons why this may be advan-
tageous to the virus as, for instance, it may favor persist-
ence of these infected cells by reducing the virus
replication to a level that permits escape from the adaptive
response. However this direct stimulation of innate im-
munity by Tat may also be responsible for the persistent
immune activation and the more striking IFN signature
observed in species that progress to AIDS [54-56]. It is
unclear whether this happens in all species infected by
lentiviruses or is more overt in species where the virus is
pathogenic. When we analyzed the modulation of a lim-
ited subset of ISG genes in AIDS resistant species by HIV
Tat or HIV and SIVmac, it appeared that their induction
was not as clear-cut in AIDS-resistant species as it is in
AIDS susceptible [57,58]. It is possible that coevolution of
host and virus selected for viral or host proteins that avoid
the effects that are most deleterious to the host. More ex-
tensive studies with matched viruses, Tat proteins, and
primary cells from different primate species are necessary
to reach a final verdict on this issue.Methods
Cells and viruses
Peripheral blood mononuclear cells were isolated from
blood by Ficoll-gradient centrifugation. Monocytes were
isolated by negative selection with Monocyte Isolation
Kit II (Miltenyi Biotec, Auburn, CA) according to the
manufacturer’s instructions. The monocytes were differ-
entiated into iDC by culturing them with human recom-
binant GM-CSF and IL-4 (R&D Systems, Minneapolis,
MN) for six days [9] or into MDM, culturing them with
human recombinant M-CSF (R&D Systems, Minneapolis,
MN) for 7 days. HIV-1SF2 with the first exon of Tat
truncated at position 59 and the second exon deleted was
generated by three substitutions to the HIV-1SF2 sequence
(accession number K02007): C6017T, C6026T, and C6035T.
These substitutions replaced the amino acid glutamine
with a stop codon at each position in the Tat sequence
without affecting the amino acid sequence of Rev. HIV-1
infection was done with an amount of virus equivalent to
20 ng of p24 per 106 iDC or MDM.
Recombinant adenoviruses Ad-tTA, Ad-TatSF2, Ad-
TatHXB2, Ad-TatSF2C25,30,34S, Ad-TatSF21-58, and
Ad-TatSF21-72, Ad-TatSF2A58T, Ad-TatSF2E86-E92A,
Ad-TatSF2K28A,K50A, Ad-TatSF2G48-R57A and their
flagged version were constructed according to established
protocols [59] and produced in 293 cells (ATCC® CRL-
1573™). The Tat coding region was cloned into the vector
pAd-TRE-MCS1, which is a first generation serotype 5
adenovirus vector that has the genes E1 and E3 deleted. Tat
is under a tetracycline inducible promoter in this vector
and is expressed only in cells co-infected with Ad-tTA,
which expresses the tetracycline responsive transactivator.
106 iDC were infected with 5 plaque-forming units (PFU)
per cell of both Ad-tTA and the Ad-Tat constructs.
As a control iDCs were also treated with 100 U/ml of
human IFN-α2a, IFN-β1a (PBL Biomedical Laboratories,
Piscataway, NJ), and IFN-γ (R&D Systems, Minneapolis,
MN). The K562 cell line (ATCC® CCL-243™), which lacks
the entire locus for Type I interferons [60], was used to
elucidate the role of Type I IFNs play in the observed gene
modulation [61-63]. The U5A cell line was a gift of
Dr. George Stark (Cleveland Clinic).
RNA isolation and quantitative RT-PCR
The growth media of cells and the cells were collected
0 h, 5 h, 10 h, 20 h, and 30 h post infection. The cells
were collected in Trizol® (Invitrogen, Carlsbad, CA) to
isolate total RNA according to the manufacturer’s in-
structions. The RNA was treated with 4 U of DNase I
(Ambion, Austin, TX) and purified with Trizol® LS.
200 ng of RNA was used as a template in reverse tran-
scription with iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). cDNA was amplified using primers
specific for Tat, the selected subset of ISG, IFN-α, IFN-β,
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primers that anneal to regions conserved in the subtypes.
Real-time PCR was performed with the iTaq SYBR Green
Supermix With ROX kit (Bio-Rad, Hercules, CA) in the
ABI Prism 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), β-actin, or 18S RNA levels were
used to normalize the amount of RNA in samples. The
levels of Tat mRNA were used to normalize the levels of
infection among different cultures. To measure the num-
ber of IFN-β mRNA copies in infected iDC, we compared
the relative RNA amount measured by quantitative
RT-PCR to IFN-β mRNA standards. To generate the
standards, we cloned the IFN-β gene under a T7 pro-
moter and made mRNA with mMessage Machine kit
with poly A tailing kit (Ambion, Austin, TX) according to
the manufacturer’s instructions.
Gene expression analysis
The RNA from iDC and MDM infected with the Ad-
Tats was analyzed with the Human Genome U133 Plus
2.0 Array and RNA from iDC infected with HIV-1 with
the Human Genome U133 Array (Affymetrix, Santa
Clara, CA). Values in the raw data below 100 were
floored to 100. Expression levels were compared to RNA
from uninfected cells and cells infected with Ad-tTA
alone as a control. Gene up-regulation was examined
only for transcripts from Ad-Tat infected cells that were
present according to the detection call and down-
regulation only for genes that were present in the unin-
fected and Ad-tTA-infected controls.
ELISA
Cytokine levels were measured in cell culture growth
medium by ELISA, performed according to the manu-
facturer’s instructions. We used the following ELISA
kits: human CXCL10/IP-10 and CXCL9/MIG DuoSet®
ELISA Development System (R&D Systems, Minneap-
olis, MN), Human IFN Beta ELISA Kit (PBL Biomedical
Laboratories, Piscataway, NJ) and Human Interferon-β
ELISA Kit (TFB, Inc., Tokyo, Japan). The p24 concentra-
tion of the amplified HIV-1 virus was measured with
HIV-1 p24 ELISA kit (PerkinElmer™ Life Sciences, Inc.,
Boston, MA). LTR transactivation in HeLa-CD4-LTR-β-
gal cells was measured with β-Galactosidase Enzyme
Assay System with Reporter Lysis Buffer (Promega,
Madison, WI).
Luciferase assay
For luciferase assays, cells were transfected with
MAP2K6- (-991 to -1 nucleotides from MAP2K6 start
site), MAP2K3- (-1013 to -1), IRF7- (-1018 to -1) lucifer-
ase vectors (SwitchGear Genomics, Carlsbad, CA, cat. #
S710112, S718628, S721774) and then infected withAd-tTA or Ad-TatSF2, Ad-TatSF21-72, Ad-TatSF21-58,
or Ad-TatSF2K28,50A and Ad-tTA. Cell lysates were
assayed for firefly and Renilla luciferase activities
(Promega, Madison). For the CDK9 inhibition, cells
were treated with Flavopiridol (Alvocidib) at 70 nM
(AdooQ.com Biosciences, Irvine, CA). In the case of
the Sp1 inhibition, cells were treated with WP631
dihydrochloride at 0.3ug/ml (Santa Cruz Biotechnology,
Dallas, TX).
Western blotting
SDS-PAGE gel electrophoresis of the cell lysates from
THP1-Mac infected with the Ad-TatSF2 and Ad-TatSF2 1-72
was carried out in the presence or absence of Flavopiridol
or WP631 according to published procedures [64]. An
anti-FLAG antibody was used for Tat detection and anti-B-
actin antibody as control (Santa Cruz Biotechnology,
Dallas, TX).
Analysis of ISG-related protein expression by intracellular
cytokine staining (ICS)
After 7 days of infection with HIVSF2 or HIVSF2Δ2exon-
Tat the cultures were treated with Brefeldin A (BD Bio-
sciences) the 16 h before staining and FACS. Anti HIV
gp120 Strain IIIB FITC (US Biological) was used to stain
infected cells and set the gate for the Env + cells only.
After permeabilization with Perm solution (BD bio-
science) cells were ICS stained with the followings anti-
bodies: efluor660-MCP-2, PE-HuMig, PE-MCP-3
(eBioscience), Alexa647-IRF-7, Pacific blue-Stat-1, PE-
IP-10, PE-TRAIL (BD biosciences) and uncogugated-
MAP2K6 (Abcam) was used with a PECy7-conjugated
secondary antibody. Flow cytometric analysis to evaluate
MFI was performed using FACS Canto (BD Biosciences)
and FlowJo v9.1 (TreeStar, Ashland, OR).
Statistical analysis
Calculations and statistical analyses were performed
using GraphPad Prism version 3 software. Between-
group comparisons were carried out by two-tailed, t test
or Mann-Whitney test. Within group comparisons were
done by one-way ANOVA followed by Bonferroni post-
hoc test. Results of statistical analyses were considered
significant if they produced p values ≤ 0.05.
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